MedTrace Logo

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

NCT00866528 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-11-13

No results posted yet for this study

Summary

The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.

Conditions

  • Lung Cancer, Non-Small Cell

Interventions

DRUG

pazopanib

oral pazopanib once daily (Phase I starting dose 800 mg)

DRUG

paclitaxel

paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-09
Primary Completion
2012-10-25
Completion
2012-10-25

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866528 on ClinicalTrials.gov